— Published date: 1/14/2026
Value Proposition: Fusion protein that can be used to prevent and treat arthritogenic alphavirus infections.
Technology Description
Researchers at Washington University in St. Louis have identified MXRA8 (matrix remodeling associated protein 8) protein as a key recepto…
— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
— Published date: 1/14/2026
Value Proposition: Soluble engineered decoy receptor protein that on its own can be used to treat multiple alphavirus types.
Technology Description
Researchers at Washington University in St. Louis have developed a composition of matter that consists of a mutagenized…
— Published date: 1/14/2026
Value Proposition: First antiviral treatment that uses soluble receptors to treat yellow fever.
Technology Description
Researchers at Washington University in St. Louis have developed new soluble receptor decoy Fc-fusion protein inhibitors for the treatment of yellow f…
— Technology Description
Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
